Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 1, 2018 Category: Nuclear Medicine Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 1, 2018 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 1, 2018 Category: Nuclear Medicine Source Type: research
Imaging thrombosis with 99mTc-labeled RAM.1-antibody in vivo
Platelets play a major role in thrombo-embolic diseases, notably by forming a thrombus that can ultimately occlude a vessel. This may provoke ischemic pathologies such as myocardial infarction, stroke or peripheral artery diseases, which represent the major causes of death worldwide. The aim of this study was to evaluate the specificity of radiolabeled Rat-Anti-Mouse antibody (RAM.1). (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 16, 2018 Category: Nuclear Medicine Authors: Ali Ouadi, Virgile Bekaert, Nicolas Receveur, Lionel Thomas, Fran çois Lanza, Patrice Marchand, Christian Gachet, Pierre H. Mangin, David Brasse, Patrice Laquerriere Source Type: research
Imaging Thrombosis with 99mTc-labeled RAM.1-Antibody in vivo
Platelets play a major role in thrombo-embolic diseases, notably by forming a thrombus that can ultimately occlude a vessel. This may provoke ischemic pathologies such as myocardial infarction, stroke or peripheral artery diseases, which represent the major causes of death worldwide. The aim of this study was to evaluate the specificity of radiolabeled Rat-Anti-Mouse antibody (RAM.1). (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 16, 2018 Category: Nuclear Medicine Authors: Ali Ouadi, Virgile Bekaert, Nicolas Receveur, Lionel Thomas, Fran çois Lanza, Patrice Marchand, Christian Gachet, Pierre H. Mangin, David Brasse, Patrice Laquerriere Source Type: research
Preliminary evaluation of 18F-labeled LLP2A-trifluoroborate conjugates as VLA-4 ( α4β1 integrin) specific radiotracers for PET imaging of melanoma
The transmembrane α4β1 integrin receptor, or very-late antigen 4 (VLA-4), is associated with tumor metastasis and angiogenesis, the development of chemotherapeutic drug resistance, and is overexpressed in multiple myelomas, osteosarcomas, lymphomas, leukemias, and melanomas. The peptidomimetic, LLP2A, is a high-aff inity ligand with specificity for the extracellular portion of VLA-4 and several conjugates have been evaluated in vivo by NIR-fluorescence, 111In-SPECT and 68Ga- and 64Cu-PET imaging, but to date, not with 18F-PET. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 12, 2018 Category: Nuclear Medicine Authors: Áron Roxin, Chengcheng Zhang, Sungjoon Huh, Mathieu L. Lepage, Zhengxing Zhang, Kuo-Shyan Lin, François Bénard, David M. Perrin Source Type: research
Preliminary evaluation of 18F-labeled LLP2A-trifluoroborate conjugates as VLA-4 ( α4β1 integrin) specific radiotracers for PET imaging of melanoma
The transmembrane α4β1 integrin receptor, or very-late antigen 4 (VLA-4), is associated with contributing to tumor metastasis and angiogenesis, the development of chemotherapeutic drug resistance, and is overexpressed in multiple myelomas, osteosarcomas, lymphomas, leukemias, and melanomas. The peptidomimetic, LLP2 A, is a high-affinity ligand with specificity for the extracellular portion of VLA-4 and several conjugates have been evaluated in vivo by NIR-fluorescence, 111In-SPECT and 68Ga- and 64Cu-PET imaging, but to date, not with 18F-PET. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 12, 2018 Category: Nuclear Medicine Authors: Áron Roxin, Chengcheng Zhang, Sungjoon Huh, Mathieu L. Lepage, Zhengxing Zhang, Kuo-Shyan Lin, François Bénard, David M. Perrin Source Type: research
A trithiol bifunctional chelate for 72,77As: A matched pair theranostic complex with high in vivo stability
Trithiol chelates are suitable for labeling radioarsenic (72As: 2.49 MeV β+, 26 h; 77As: 0.683 MeV β−, 38.8 h) to form potential theranostic radiopharmaceuticals for PET imaging and therapy. To investigate the in vivo stability of trithiol chelates complexed with no carrier added (nca) radioarsenic, a bifunctional trithiol chelate was developed, and conj ugated to bombesin(7–14)NH2 as a model peptide. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 10, 2018 Category: Nuclear Medicine Authors: Yutian Feng, Anthony J. DeGraffenreid, Michael D. Phipps, Tammy L. Rold, Nkemakonam C. Okoye, Fabio A. Gallazzi, Charles L. Barnes, Cathy S. Cutler, Alan R. Ketring, Timothy J. Hoffman, Silvia S. Jurisson Source Type: research
In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three five-membered azaheterocyclic arms for complexation of the PET nuclides gallium-68 and copper-64. The main objective of this study was to evaluate the stability and pharmacokinetics of 68Ga- and 64Cu-complexes of the bifunctional chelator NODIA-Me 1 covalently bound to a PSMA targeting vector in vivo. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 10, 2018 Category: Nuclear Medicine Authors: Tilman L äppchen, Yvonne Kiefer, Jason P. Holland, Mark D. Bartholomä Source Type: research
A Trithiol Bifunctional Chelate for 72,77As: a Matched Pair Theranostic Complex with High in vivo Stability
Trithiol chelates are suitable for labeling radioarsenic (72As: 2.49 MeV β+, 26 h; 77As: 0.683 MeV β−, 38.8 h) to form potential theranostic radiopharmaceuticals for PET imaging and therapy. To investigate the in vivo stability of trithiol chelates complexed with no carrier added (nca) radioarsenic, a bifunctional trithiol chelate was developed, and conjugated to bom besin(7-14)NH2 as a model peptide. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 10, 2018 Category: Nuclear Medicine Authors: Yutian Feng, Anthony J. DeGraffenreid, Michael D. Phipps, Tammy L. Rold, Nkemakonam C. Okoye, Fabio A. Gallazzi, Charles L. Barnes, Cathy S. Cutler, Alan R. Ketring, Timothy J. Hoffman, Silvia S. Jurisson Source Type: research
Evaluation of 177Lu[Lu]-CHX-A ″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII
Due to their infiltrative growth behavior, gliomas have, even after surgical resection, a high recurrence tendency. The approach of intracavitary radioimmunotherapy (RIT) is aimed at inhibiting tumor re-growth by directly administering drugs into the resection cavity (RC). Direct application of the radioconjugate into the RC has the advantage of bypassing the blood-brain barrier, which allows the administration of higher radiation doses than systemic application. Carbonic anhydrase XII (CA XII) is highly expressed on glioma cells while being absent from normal brain and thus an attractive target molecule for RIT. (Source: ...
Source: Nuclear Medicine and Biology - March 4, 2018 Category: Nuclear Medicine Authors: L. Fiedler, M. Kellner, A. Gosewisch, R. Oos, G. B öning, S. Lindner, N. Albert, P. Bartenstein, H.-J. Reulen, R. Zeidler, F.J. Gildehaus Source Type: research
Evaluation of 177Lu- CHX-A ´´-DTPA-6A10 Fab as a Radioimmunotherapy Agent Targeting Carbonic Anhydrase XII
Due to their infiltrative growth behavior, gliomas have, even after surgical resection, a high recurrence tendency. The approach of intracavitary radioimmunotherapy (RIT) is aimed at inhibiting tumor re-growth by directly administering drugs into the resection cavity (RC). Direct application of the radioconjugate into the RC has the advantage of bypassing the blood-brain barrier, which allows the administration of higher radiation doses than systemic application. Carbonic anhydrase XII (CA XII) is highly expressed on glioma cells while being absent from normal brain and thus an attractive target molecule for RIT. (Source: ...
Source: Nuclear Medicine and Biology - March 4, 2018 Category: Nuclear Medicine Authors: L. Fiedler, M. Kellner, A. Gosewisch, R. Oos, G. B öning, S. Lindner, N. Albert, P. Bartenstein, H.-J. Reulen, R. Zeidler, F.J. Gildehaus Source Type: research
Robust high-yield ~1 TBq production of cyclotron based sodium [99mTc]pertechnetate
This paper presents the irradiation and processing of high-current 100Mo targets at the University of Alberta (UofA) in a GMP compliant setting. For purpose of comparison with a second production facility, additional studies at Centre Hospitalier Universitaire de Sherbrooke (CHUS) are also described. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 2, 2018 Category: Nuclear Medicine Authors: J.D. Andersson, B. Thomas, S.V. Selivanova, E. Berthelette, J.S. Wilson, A.J.B. McEwan, K. Gagnon Source Type: research
Robust high-yield ~1 TBq production of cyclotron based sodium [99mTc]pertechnetate
This paper presents the irradiation and processing of high-current 100Mo targets at the University of Alberta (UofA) in a GMP compliant setting. For purpose of comparison with a second production facility, additional studies at Centre Hospitalier Universitaire de Sherbrooke (CHUS) are also described. Introduction:>70% of today's diagnostic radiopharmaceuticals are based on 99mTc, however the conventional supply chain for obtaining 99mTc is fragile. The aim of this work was to demonstrate reliable high yield production and processing of 99mTc with medium-energy, high-current, cyclotrons. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - March 2, 2018 Category: Nuclear Medicine Authors: J.D. Andersson, B. Thomas, S.V. Selivanova, E. Berthelette, J.S. Wilson, A.J.B. McEwan, K. Gagnon Source Type: research
